Form 4: Edgewise Therapeutics Director Peter Thompson Acquires Stock Options
SEC Form 4 Filing
Director Peter Thompson acquired 20,594 stock options in Edgewise Therapeutics on June 10, 2024.
Summary
- Peter Thompson, a director of Edgewise Therapeutics, acquired 20,594 stock options on June 10, 2024.
- The exercise price of these options is $17.13.
- The options vest on the earlier of June 10, 2025, or the business day prior to the 2025 annual meeting of stockholders.
- The options expire on June 10, 2034.
- Following the transaction, Thompson directly owns 20,594 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director. While insider ownership is generally viewed positively, this is a standard part of compensation.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of transaction: Peter Thompson acquired stock options. |
| 06/10/2025 | Stock options vest on the earlier of this date or the business day prior to the 2025 annual meeting of stockholders. |
| 06/10/2034 | Expiration date of the stock options. |
| 06/12/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.